Clinical trials

The study is designed to test the hypothesis that the same dose of TXA prior to delivery or pre-cord clamp will be sufficient to achieve hemorrhage prevention targets and define dosing schema for intravenous (IV) and intramuscular (IM).

In this multi-site, observational prospective study of pregnant people and their infants, we will assess the timing of pregnancy diversification of the vaginal microbiome. We will also explore the driving hormonal and immunological influences on vaginal microbiome diversification as well as the mother to infant microbiome transfer based on the diversification of the vaginal microbiome.

The purpose of this study is to create a repository of coded specimens and data to support and advance future research studies for pregnancy-related disorders.

The study is designed to use ultrasound to image the pelvic floor muscles before and after delivery to determine what characteristics can lead to muscle injury during a vaginal delivery.

The Yaari Extractor Investigational Device is intended for treatment of shoulder dystocia (SD). The purpose is to create a more effective and controlled response to SD compared to the current standard of care. Furthermore, to decrease risks and complications to mother and baby.

The objective of this study is to analyze the relationships between maternal SARS-CoV-2 infection, placental pathology/biology, and offspring neurodevelopmental outcomes.

The study is designed to examine difference the between two standard of care antibiotic regimens with a secondary aim to determine if the different antibiotic regimens could differ by race.

The purpose of this study is to gather safety information, meaning the type and frequency of any possible side effects in pregnant women and their infants when the GBS6 is given. This study will also assess the ability of GBS6 to stimulate an immune response by measuring the antibodies against the 6 most common serotypes of GBS.

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.